GEM2010MAS65: Sequential versus Alternating VMP and Rd for Newly Diagnosed Multiple Myeloma


GEM2010MAS65: Sequential versus Alternating VMP and Rd for Newly Diagnosed Multiple Myeloma
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Sagar Lonial, MD (1/22/14)
Mateos MV et al. Comparison of sequential vs alternating administration of bortezomib, melphalan and prednisone (VMP) and lenalidomide plus dexamethasone (Rd) in elderly patients with newly diagnosed multiple myeloma (MM): GEM2010MAS65 trial. Proc ASH 2013;Abstract 403.

Dr Lonial is Professor, Vice Chair of Clinical Affairs and Director of Translational Research for the B-Cell Malignancy Program in the Department of Hematology and Medical Oncology at the Emory University School of Medicine Winship Cancer Institute in Atlanta, Georgia.